juststock
NKGen Biotech (NASDAQ:NKGN) stated it has dosed its first affected person in a Part 1/2a research of its cell remedy SNK01 within the remedy of reasonable Alzheimer’s illness, AD.
The biotech firm stated the Part 1 portion of the research will assist decide the utmost tolerated and/or beneficial dose for the Part 2 portion, which shall be a randomized double-blind trial evaluating the protection and efficacy of the remedy in AD.
NKGen stated the primary affected person acquired a dose of 6 billion cells, 50% greater than the utmost dose in a previous Part 1 research. The corporate stated it hopes the elevated dose will present “even larger cognitive profit and larger results in protein and neuroinflammation ranges.
The corporate plans to conduct an interim information readout from the research in Q3 2024.
NKGen went public by means of a SPAC merger with Graf Acquisition Corp. IV earlier this yr.
